Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet

Volumn 385, Issue 9980, 2015, Pages 1853-1862

  Moskowitz, Craig H ^a   Nademanee, Auayporn ^b   Masszi, Tamas ^c   Agura, Edward ^d   Holowiecki, Jerzy ^e   Abidi, Muneer H ^f   Chen, Andy I ^g   Stiff, Patrick ^h   Gianni, Alessandro M ⁱ   Carella, Angelo ^j   Osmanov, Dzhelil ^k   Bachanova, Veronika ^l   Sweetenham, John ^m   Sureda, Anna ⁿ   Huebner, Dirk ^o   Sievers, Eric L ^p   Chi, Andy ^o   Larsen, Emily K ^p   Hunder, Naomi N ^p   Walewski, Jan ^q  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Szent Istvan and Szent Laszlo Hospitals   (Hungary)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f KARMANOS CANCER INSTITUTE   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j UNIVERSITY OF GENOA   (Italy)

^k N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^l UNIVERSITY OF MINNESOTA   (United States)

^m UNIVERSITY OF UTAH   (United States)

ⁿ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^o TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^p SEATTLE GENETICS INC   (United States)

^q INSTITUTE OF ONCOLOGY   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; PLACEBO; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAC10-VCMMAE;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; COMPUTER ASSISTED TOMOGRAPHY; CONSOLIDATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HODGKIN DISEASE; HUMAN; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SENSORY NEUROPATHY; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADOLESCENT; ADVERSE EFFECTS; CLINICAL TRIAL; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RECURRENT DISEASE; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CONSOLIDATION CHEMOTHERAPY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929510996     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60165-9     Document Type: Article

References (33)

1. N Schmitz, B Pfistner, M Sextro et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial Lancet 359 2002 2065 2071
2. DC Linch, D Winfield, AH Goldstone et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial Lancet 341 1993 1051 1054
3. A Sureda, M Constans, A Iriondo et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse Ann Oncol 16 2005 625 633
4. NS Majhail, DJ Weisdorf, TE Defor et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma Biol Blood Marrow Transplant 12 2006 1065 1072
5. B Sirohi, D Cunningham, R Powles et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma Ann Oncol 19 2008 1312 1319
6. T Hahn, PL McCarthy, J Carreras et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma Biol Blood Marrow Transplant 19 2013 1740 1744
7. P Brice, R Bouabdallah, P Moreau et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moelle Bone Marrow Transplant 20 1997 21 26
8. SD Smith, CH Moskowitz, R Dean et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres Br J Haematol 153 2011 358 363
9. CH Moskowitz, MJ Matasar, AD Zelenetz et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma Blood 119 2012 1665 1670
10. A Josting, J Franklin, M May et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group J Clin Oncol 20 2002 221 230
11. A Josting, H Muller, P Borchmann et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma J Clin Oncol 28 2010 5074 5080
12. C Martinez, C Canals, B Sarina et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation Ann Oncol 24 2013 2430 2434
13. CH Moskowitz, SD Nimer, AD Zelenetz et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model Blood 97 2001 616 623
14. DE Reece, MJ Barnett, JD Shepherd et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy Blood 86 1995 451 456
15. S Akhtar, AS Al-Sugair, M Abouzied et al. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT Bone Marrow Transplant 48 2013 1530 1536
16. AJ Moskowitz, MA Perales, T Kewalramani et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma Br J Haematol 146 2009 158 163
17. HC Fung, P Stiff, J Schriber et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma Biol Blood Marrow Transplant 13 2007 594 600
18. F Morschhauser, P Brice, C Ferme et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group J Clin Oncol 26 2008 5980 5987
19. AP Rapoport, C Guo, A Badros et al. Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma Bone Marrow Transplant 34 2004 883 890
20. B von Tresckow, A Skotnicki, I Lisukov et al. A phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with hodgkin lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation Blood 122 2013 4648 (abstr).
21. A Younes, AK Gopal, SE Smith et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma J Clin Oncol 30 2012 2183 2189
22. A Gopal, R Chen, S Smith et al. Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory hodgkin lymphoma Blood 21 2013 4382 (abstr).
23. BD Cheson, B Pfistner, ME Juweid et al. Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
24. M Tomblyn, T Chiller, H Einsele et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective Biol Blood Marrow Transplant 15 2009 1143 1238
25. S Arai, M Fanale, S DeVos et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant Leuk Lymphoma 54 2013 2531 2533
26. NL Bartlett, R Chen, MA Fanale et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies J Hematol Oncol 7 2014 24
27. SM Ansell, AM Lesokhin, I Borrello et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N Engl J Med 372 2015 311 319
28. A Younes, A Sureda, D Ben-Yehuda et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study J Clin Oncol 30 2012 2197 2203
29. AK Gopal, R Chen, SE Smith et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma Blood 2014 10.1182/blood-2014-08-595801 published online Dec 22.
30. DE Reece, JM Connors, JJ Spinelli et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy Blood 83 1994 1193 1199
31. C Ferme, N Mounier, M Divine et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial J Clin Oncol 20 2002 467 475
32. AJ Moskowitz, J Yahalom, T Kewalramani et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma Blood 116 2010 4934 4937
33. JP Smeltzer, AF Cashen, Q Zhang et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation Biol Blood Marrow Transplant 17 2011 1646 1652